An Innovative Delivery System of Oxygen-Releasing Nanospheres and Self-Healing Hydrogels Enhances the Therapeutic Effectiveness of Bone Marrow Mesenchymal Stem Cells for Chronic Limb-Threatening Ischemia
Moyan Zhao,Zixuan Zhou,Amir Sherchan,Weizhong Yuan,Xiaoyun Xie,Maoquan Li
DOI: https://doi.org/10.2147/ijn.s483541
IF: 7.033
2024-11-27
International Journal of Nanomedicine
Abstract:Moyan Zhao, 1 Zixuan Zhou, 2 Amir Sherchan, 1 Weizhong Yuan, 2 Xiaoyun Xie, 3 Maoquan Li 1, 3 1 Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, People's Republic of China; 2 Key Laboratory of Advanced Civil Materials of Ministry of Education, School of Materials Science and Engineering, Tongji University, Shanghai, 201804, People's Republic of China; 3 Department of Intervention and Vascular Surgery, Shanghai Tenth People's Hospital, Shanghai, 200092, People's Republic of China Correspondence: Maoquan Li, Department of Intervention and Vascular Surgery, Shanghai Tenth People's Hospital, Shanghai, 200092, People's Republic of China, Email Purpose: Bone marrow mesenchymal stem cells (BMSCs) have emerged as promising candidate for postoperative therapeutics in chronic limb-threatening ischemia (CLTI). Nevertheless, their effectiveness is limited by their low survival rate and impaired functionality in the ischemic microenvironment. To overcome these challenges, we have devised an innovative delivery approach to support the utilization of BMSCs in CLTI therapy. Methods: We synthesized oxygen-releasing nanospheres and self-healing hydrogels. The in vivo functionality of the hydrogel-nanosphere delivery system was evaluated via a multimodality animal live imaging system. A unilateral lower limb ischemia model was established in mice, and a delivery system loaded with BMSCs was administered. The experimental groups included normal mice, ischemic mice, ischemic mice treated with BMSCs in PBS, and ischemic mice treated with BMSCs in the delivery system. Blood perfusion was quantitatively measured via a laser doppler flowmeter (LDF). Immunofluorescence, Masson's trichrome staining, immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) were also used. Results: For cell viability analysis 80 μg.mL − 1 was considered the optimal concentration for cell survival. In vivo, 18 days after injection, the cell membrane fluorescence signal in the delivery system was significantly greater (5.655 10 ± 8.226 8 ) p/s/cm2/sr than that in the other groups (p=0.043). Ischemic mice treated with BMSCs in the delivery system presented an improved limb salvage rate (0.926± 0.12)% compared with that of ischemic mice treated with BMSCs in PBS (0.841± 0.029)% at the 5th week after ischemia establishment (p=0.0033). Conclusion: Our findings suggest that the survival time of BMSCs is prolonged in this innovative delivery system. The combination of nanospheres and hydrogels effectively restored vascular blood perfusion while exerting minimal toxicity on BMSCs. This novel approach combining oxygen-releasing nanospheres and self-healing hydrogels as a delivery system represents an advancement in enhancing the functionality of BMSCs to treat CLTI. Keywords: nanoscale microsphere, stem cell therapy, delivery system, chronic vascular disease, revascularization, tissue recovery Graphical Chronic limb-threatening ischemia (CLTI) is a serious vascular condition characterized by significantly reduced blood supply to the extremities, 1 leading to tissue hypoxia, persistent pain, ulceration, and in severe cases, amputation. 2–4 Medication is often ineffective because of the lack of blood perfusion, 5 and approximately 50% of patients with subpatellar lesions do not meet the criteria for surgical revascularization. 6,7 Research on various innovative treatments aimed at restoring blood flow to affected tissues, including angiogenesis therapy, stem cell therapy, gene therapy, hyperbaric oxygen therapy and nanomedicine is ongoing. 8 The use of nanoparticles to deliver drugs directly to ischemic tissues can improve drug efficacy and reduce side effects. Stem cell therapy has advantages in terms of tissue recovery, 9,10 with mesenchymal stem cells (MSCs) facilitating the development of collateral circulation in ischemic arteries, 11 thereby alleviating ischemic symptoms and decreasing the risk of amputation. 12,13 Bone marrow mesenchymal stem cells (BMSCs) are particularly promising because of their relatively easy accessibility and lack of ethical controversy. They can differentiate into osteoblasts, chondrocytes, adipocytes and myocytes, making them strong candidates for transplantation. 14 Their unique properties, including self-renewal, multipotency, and immunomodulatory capacities, make them complimentary treatments for assisting in neovascularization and tissue regeneration. 15 However, the treatment effectiveness of BMSCs is hindered by their low survival rate in the isc -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology